Notice of Modification of Eligibility Restriction of PAR-18-265 "Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 Clinical Trial Optional)"
Notice Number:
NOT-GM-18-026
Key Dates
Release Date: April 19, 2018
Related Announcements
PAR-18-265
Issued by
National Institute of General Medical Sciences (NIGMS)
Purpose
This Notice modifies the eligibility restrictions of PAR-18-265 as follows:
Part 2. Section III.1 Eligible Applicants
Eligible Organizations
Current eligibility:
The following additional restrictions and considerations apply when submitting an application to this FOA:
- Institutions (normally identified by a unique NIH IPF number) that currently hold an active NIH-funded clinical and translational center award may not apply. However, these institutions can partner or collaborate with the lead applicant for an IDeA-CTR. For the purposes of this FOA, these awards include the following:
- Clinical and Translational Science Award (CTSA) funded by the National Center for Advancing Translational Sciences (NCATS)
- Research Centers in Minority Institutions (RCMI) with clinical and translational Research focus (U54 awards) funded by the National Institute on Minority Health and Health Disparities (NIMHD).
- IDeA-CTR awards cannot run concurrently with CTSA or RCMI awards with clinical and translational focus. If an institution receives a CTSA or RCMI award after an IDeA-CTR award is funded, the IDeA-CTR award must be relinquished.
- Only one IDeA-CTR award can be made per eligible IDeA state. An IDeA-CTR award is expected to be a statewide (and/or interstate) resource and the lead institution must communicate and coordinate with and include other appropriate institutions/organizations within the state when submitting an application.
Modified eligibility:
The following additional restrictions and considerations apply when submitting an application to this FOA:
- Institutions (normally identified by a unique NIH IPF number) that currently hold an active NIH-funded clinical and translational center award (e.g. Clinical and Translational Science Award [CTSA] funded by the National Center for Advancing Translational Sciences [NCATS] or Research Centers in Minority Institutions [RCMI] Infrastructure for Clinical and Translational Research [RCTR U54 awards made in response to PAR-13-279] funded by the National Institute on Minority Health and Health Disparities [NIMHD]) may apply but should consider the following restrictions on awards:
- IDeA-CTR awards cannot run concurrently with CTSA or RCTR awards. If an institution receives a CTSA or RCTR award after an IDeA-CTR award is funded, the IDeA-CTR award must be relinquished. Conversely, an IDeA-CTR award will not be made while a CTSA or RCTR award is active.
- Only one IDeA-CTR award can be made per eligible IDeA state. An IDeA-CTR award is expected to be a statewide (and/or interstate) resource and the lead institution must communicate and coordinate with and include other appropriate institutions/organizations within the state(s) when submitting an application.
All other aspects of this FOA remain the same.
Inquiries
Please direct all inquiries to:
J. Rafael Gorospe, M.D., Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-435-0832
Email: gorospejr@mail.nih.gov